Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
1(20%)
Results Posted
67%(2 trials)
Terminated
1(20%)

Phase Distribution

Ph early_phase_1
1
20%
Ph phase_4
1
20%
Ph phase_2
1
20%
Ph phase_3
2
40%

Phase Distribution

1

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Early Phase 1First-in-human
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
2(40.0%)
Phase 4Post-market surveillance
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(3)
Terminated(1)

Detailed Status

Completed3
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (20.0%)
Phase 21 (20.0%)
Phase 32 (40.0%)
Phase 41 (20.0%)

Trials by Status

terminated120%
active_not_recruiting120%
completed360%

Recent Activity

1 active trials
Showing 5 of 5
active_not_recruitingphase_3

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer

NCT03528694
completedphase_2

A Pilot Study of the Effects of BCG Immunization on CSF and Blood-based Biomarkers in Older Adults.

NCT04507126
completedphase_4

Comparison of BCG RIVM and Russian Strains for Treating Non-Muscle-Invasive Bladder Cancer (NMIBC)

NCT06767982
completedearly_phase_1

PRIME: Pilot Study Evaluating Percutaneous Vaccination of BCG for Bladder Cancer

NCT02326168
terminatedphase_3

Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients

NCT00974818

Clinical Trials (5)

Showing 5 of 5 trials
NCT03528694Phase 3

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer

Active Not Recruiting
NCT04507126Phase 2

A Pilot Study of the Effects of BCG Immunization on CSF and Blood-based Biomarkers in Older Adults.

Completed
NCT06767982Phase 4

Comparison of BCG RIVM and Russian Strains for Treating Non-Muscle-Invasive Bladder Cancer (NMIBC)

Completed
NCT02326168Early Phase 1

PRIME: Pilot Study Evaluating Percutaneous Vaccination of BCG for Bladder Cancer

Completed
NCT00974818Phase 3

Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients

Terminated

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5